Opportunity Information: Apply for RFA HL 09 007
Apply for RFA HL 09 007
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Airway Smooth Muscle Function and Targeted Therapeutics in Human Asthma (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research.
- This funding opportunity was created on Oct 8, 2008 and posted on Oct 8, 2008.
- Applicants must submit their applications by Jan 6, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,200,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 8 candidate(s).
- Eligible applicants include: Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Small businesses Special district governments Public and State controlled institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public housing authorities/Indian housing authorities County governments Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Airway Smooth Muscle Function and Targeted Therapeutics in Human Asthma (R01) is an NHLBI (NIH) research funding opportunity designed to push asthma research beyond broad airway inflammation and focus directly on airway smooth muscle (ASM) as a key driver of disease. The central aim is to support projects that clarify how ASM contributes to the onset and progression of human asthma and, importantly, to translate that improved understanding into the identification of new, more precise therapeutic targets. In other words, the FOA is looking for R01-level studies that treat ASM not just as a passive tissue that tightens during an asthma attack, but as an active participant in asthma biology whose functions may shape airway narrowing, hyperresponsiveness, remodeling, and responses to treatment.
The award mechanism is the standard NIH Research Project Grant (R01), which generally supports hypothesis-driven, multi-year research programs with a clear scientific rationale, solid preliminary evidence when appropriate, and a well-developed plan for rigorous experimentation. The NHLBI signals that it expects full-scale research efforts that can stand on their own as substantial projects rather than small pilot studies. Applications are expected to be grounded in human asthma relevance, given the FOA title and emphasis on "human asthma," and to be oriented toward actionable insights that could inform or enable targeted therapeutics aimed at ASM-related pathways, mechanisms, or phenotypes.
In terms of funding, the NHLBI planned to commit about $4.2 million in total costs in fiscal year 2009 and up to $16.8 million over four years to support approximately eight awards. These figures reflect the program’s intended scale and competitiveness: a limited number of grants funded from a defined set-aside budget, with awards dependent on both the availability of funds and the presence of a sufficient number of high-quality, meritorious applications. The expected number of awards (8) provides a practical sense of selectivity and suggests that projects need to be especially strong in significance, innovation, approach, and potential impact on asthma treatment strategies.
Eligibility is broad and includes most major categories of research-performing organizations. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), for-profit organizations (including small businesses), and multiple levels of government entities (state, county, city/township, special district governments, independent school districts, and public housing authorities/Indian housing authorities). The FOA also explicitly includes a wide range of institution types and community-serving organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and faith-based or community-based organizations. Importantly, the eligibility listing also allows non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and certain tribal governments and tribal organizations, expanding the applicant pool beyond traditional U.S.-based academic medical centers.
Administratively, this opportunity is listed as a discretionary grant in the health area, under CFDA 93.838 (Lung Diseases Research), and it does not require cost sharing or matching. The funding opportunity number is RFA-HL-09-007, and it was posted on October 8, 2008, with an application closing date of January 6, 2009 (and an archive date of February 6, 2009). For applicants needing the full details, the FOA points to the NIH Grants Guide webpage for the complete announcement, and it provides NIH Office of Extramural Research (OER) webmaster contact information for technical access or linking issues.
Overall, the opportunity is best understood as a targeted NIH initiative to deepen mechanistic knowledge of airway smooth muscle in asthma and to use that knowledge to open up new therapeutic directions. The NHLBI’s emphasis on the "complex role" of ASM and "novel therapeutic targets" indicates interest in research that explains why ASM behaves differently in asthma, how those differences are regulated, and which molecular, cellular, or functional features of ASM can be modulated to improve clinical outcomes.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Airway Smooth Muscle Function and Targeted Therapeutics in Human Asthma (R01).
Which agency is offering this funding opportunity?
This is a research funding opportunity from the National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH).
What is the funding opportunity number (FOA number)?
The funding opportunity number is RFA-HL-09-007.
What type of grant mechanism is used?
The award mechanism is the standard NIH Research Project Grant (R01).
What does an R01 mean in this context?
In this program, NHLBI indicates it expects full-scale, hypothesis-driven, multi-year research projects with a clear scientific rationale and a well-developed experimental plan. The description signals these are intended to be substantial studies rather than small pilot efforts.
What is the main scientific focus of the FOA?
The FOA is designed to move asthma research beyond broad airway inflammation and focus directly on airway smooth muscle (ASM) as a key driver of disease. It supports research clarifying how ASM contributes to the onset and progression of human asthma and translating that understanding into new, more precise therapeutic targets.
How does this FOA describe airway smooth muscle (ASM) in asthma?
ASM is treated as more than a passive tissue that tightens during an asthma attack. The FOA frames ASM as an active participant in asthma biology that may shape airway narrowing, hyperresponsiveness, remodeling, and responses to treatment.
What kinds of research outcomes is NHLBI looking for?
Applications are expected to be oriented toward actionable insights that could inform or enable targeted therapeutics aimed at ASM-related pathways, mechanisms, or phenotypes. The emphasis is on identifying novel therapeutic targets connected to the complex role of ASM in asthma.
Is this FOA specifically focused on human asthma?
Yes. The FOA title and description emphasize "human asthma" and indicate projects should be grounded in human asthma relevance.
How much funding was planned for this initiative?
NHLBI planned to commit about $4.2 million in total costs in fiscal year 2009, and up to $16.8 million over four years.
How many awards were expected?
The FOA anticipated supporting approximately eight (8) awards.
How competitive is this opportunity based on the information provided?
The FOA describes a defined set-aside budget supporting a limited number of awards (about eight), and notes awards depend on both availability of funds and a sufficient number of high-quality, meritorious applications. This suggests a competitive program where applications likely need to be especially strong in significance, innovation, approach, and potential impact.
Are awards guaranteed if an application scores well?
No. The FOA states awards are dependent on the availability of funds and the presence of a sufficient number of high-quality applications.
What is the CFDA number associated with this opportunity?
The CFDA listing is 93.838 (Lung Diseases Research).
What type of grant is this listed as administratively?
It is listed as a discretionary grant in the health area.
Is cost sharing or matching required?
No. The opportunity states it does not require cost sharing or matching.
Who is eligible to apply?
Eligibility is broad and includes:
- Public and private institutions of higher education
- Nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status)
- For-profit organizations (including small businesses)
- Government entities (state, county, city/township, special district, independent school districts, and public housing authorities/Indian housing authorities)
- Community-serving and mission-based institutions including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and faith-based or community-based organizations
Are non-U.S. (foreign) organizations eligible?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations), as well as regional organizations and U.S. territories or possessions.
Are tribal governments or tribal organizations eligible?
Yes. The eligibility listing includes certain tribal governments and tribal organizations, and also references Tribally Controlled Colleges and Universities (TCCUs).
What was the posting date for this FOA?
The FOA was posted on October 8, 2008.
What was the application closing date?
The application closing date was January 6, 2009.
When was the archive date?
The archive date listed is February 6, 2009.
Where can applicants find the complete announcement?
The FOA points applicants to the NIH Grants Guide webpage for the complete announcement.
Who is listed for technical access or linking issues?
The FOA provides contact information for the NIH Office of Extramural Research (OER) webmaster for technical access or linking issues.
What is the overall purpose of this NHLBI initiative?
Overall, it is a targeted NIH initiative intended to deepen mechanistic knowledge of airway smooth muscle in asthma and use that knowledge to open up new therapeutic directions, including identification of more precise targets for treatment.
What specific aspects of asthma does the FOA connect to ASM?
The FOA highlights ASM as potentially shaping airway narrowing, hyperresponsiveness, airway remodeling, and responses to treatment.
Browse more opportunities from the same category: Health
Next opportunity: Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis (R21/R33)
Previous opportunity: NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 09 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 09 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis (R21/R33) Apply for RFA AI 08 055 Funding Number: RFA AI 08 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neurodevelopment and Neuroendocrine Signaling in Adolescence Relevance to Mental Health (R01) Apply for PA 09 008 Funding Number: PA 09 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neurodevelopment and Neuroendocrine Signaling in Adolescence Relevance to Mental Health (R21) Apply for PA 09 009 Funding Number: PA 09 009 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Circadian Coupled Cellular Function in Heart, Lung, and Blood Tissue (R01) Apply for RFA HL 09 012 Funding Number: RFA HL 09 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Dental Public Health Residency Training Grants Apply for HRSA 09 200 Funding Number: HRSA 09 200 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Training and Technical Assistance Cooperative Agreements (NCA) Apply for HRSA 09 193 Funding Number: HRSA 09 193 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Basic/Core Area Health Education Centers Apply for HRSA 09 123 Funding Number: HRSA 09 123 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Model State Supported Area Health Education Centers Apply for HRSA 09 124 Funding Number: HRSA 09 124 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Public Education Efforts to Increase Solid Organ Donation Apply for HRSA 09 185 Funding Number: HRSA 09 185 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Fine Mapping and Function of Genes for Type 1 Diabetes (DP3) Apply for RFA DK 08 006 Funding Number: RFA DK 08 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Characterizing the Blood Stem Cell Niche (R01) Apply for RFA HL 09 010 Funding Number: RFA HL 09 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global HIV/AIDS Nursing Initiative Apply for HRSA 09 191 Funding Number: HRSA 09 191 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Reducing Loss to Followup after Failure to Pass Newborn Hearing Screening Apply for HRSA 09 141 Funding Number: HRSA 09 141 Agency: Health Resources and Services Administration Category: Health Funding Amount: $125,000 |
| Healthy Start Initiative Eliminating Racial/Ethnic Disparities Apply for HRSA 09 130 Funding Number: HRSA 09 130 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,350,000 |
| Disparities in Perinatal Health Border, Alaska and Hawaii Apply for HRSA 09 131 Funding Number: HRSA 09 131 Agency: Health Resources and Services Administration Category: Health Funding Amount: $925,000 |
| Clinical Pharmacotherapy for PTSD Single and Collaborative Studies (R34) Apply for RFA MH 09 090 Funding Number: RFA MH 09 090 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Unintentional Poisoning from Prescription Drug Overdoses in Adults (R21) Apply for RFA CE 09 004 Funding Number: RFA CE 09 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $175,000 |
| Research Priorities in Acute Injury Care (R01) Apply for RFA CE 09 005 Funding Number: RFA CE 09 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| DRAFT PD Securing Ugandas Right to Essential Medicines (SURE) Activity Apply for 617 09 001 Funding Number: 617 09 001 Agency: Uganda USAID Kampala Category: Health Funding Amount: $45,000,000 |
| Research Grants for Preventing Violence and Violence Related Injury (R01) Apply for RFA CE 09 007 Funding Number: RFA CE 09 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 09 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.